Loading…
Chinese TCM distribution and pharmaceutical company that became notorious for a major accounting-fraud scandal in 2019.
Chinese TCM distribution and pharmaceutical company that became notorious for a major accounting-fraud scandal in 2019.
Moat: none. Diminished brand trust after a landmark accounting-fraud case damaged investor and business confidence.
Headquarters: Guangdong, China · Employees: 5,492
Size Kangmei Pharmaceutical (600518.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.77B, the 925th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥1.34 on 6 Nov 2026.
Performance Over six months the shares fell 21.6%, against -2.8% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 5.6% over the last twelve months (peer median +16.5%); the operating margin is -6.7% (peer median 11.3%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 10.9× (5th cheapest of 20).
Capital Return on invested capital runs 9.0 points below its cost of capital (5.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.97B | CN¥5.24B | CN¥5.12B | CN¥5.15B | CN¥4.17B |
| Revenue growth | — | +2% | -1% | +23% | — |
| Gross profit | CN¥850M | CN¥840M | CN¥465M | CN¥874M | CN¥372M |
| EBITDA | -CN¥3.03M | CN¥159M | -CN¥52.6M | CN¥475M | -CN¥661M |
| Net income | CN¥29.5M | CN¥10.3M | CN¥8.57M | CN¥103M | -CN¥2.69B |
| Free cash flow | CN¥11.8M | -CN¥106M | -CN¥489M | -CN¥417M | -CN¥798M |
| Capital expenditure | CN¥218M | CN¥217M | CN¥61.7M | CN¥99.7M | CN¥48.1M |
| Total debt | CN¥322M | CN¥309M | CN¥213M | CN¥306M | CN¥1.15B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical 600518.SS | $2.77B | -22% | -6% | -7% | 3.5× | n/a |
| Beijing TongRenTang 600085.SS | $5.27B | -8% | -17% | 8% | 2.4× | 2.7% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 2.0× | -0.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 1.9× | -6.3% |
| Jointown Pharmaceutical 600998.SS | $3.96B | +1% | +9% | 2% | 0.4× | 0.1% |
| Sinopharm 1099.HK | $6.83B | -4% | +3% | 3% | 0.3× | -8.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600518.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | +2.2% | 10th lowest of 21 |
| 6-month return | -21.6% | -2.8% | 4th lowest of 21 |
| Distance from 52-week high | -38.0% | -21.3% | 6th lowest of 21 |
| Revenue growth (TTM) | -5.6% | +16.5% | 8th lowest of 20 |
| Operating margin | -6.7% | 11.3% | 5th lowest of 20 |
| EV / Sales | 3.5× | 10.9× | 5th cheapest of 20 |
| ROIC minus cost of capital | -9.0 pp | +1.1 pp | 3rd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | 3.5× | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 25.3× | 25.7% | +100.1% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 16.6× | 42.1% | +22.9% |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 8.9× | 50.7% | +17.3% |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 2.1× | 7.3% | +6.5% |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 16.7× | 45.0% | +27.7% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 4.5× | 4.6% | +4.8% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 1.6× | -13.1% | +2.4% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 10.9× | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | 15.4× | n/a | n/a |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 2.4× | 49.9% | +19.3% |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 5.8× | 25.2% | +14.0% |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | 60.5× | n/a | n/a |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 14.7× | 40.1% | +6.1% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 17.5× | n/a | n/a |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 3.6× | -2.2% | +7.0% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% | -9.6% |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 6.7× | 48.9% | +367.3% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 19.3× | n/a | n/a |